{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:33:10Z","timestamp":1784745190602,"version":"3.55.0"},"reference-count":61,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"DOI":"10.1210\/jc.2012-3680","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T02:56:36Z","timestamp":1358823396000},"page":"946-953","source":"Crossref","is-referenced-by-count":64,"title":["Treat-to-target for Osteoporosis: Is Now the Time?"],"prefix":"10.1210","volume":"98","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center (E.M.L.), Albuquerque, New Mexico 87106"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[{"name":"San Francisco Coordinating Center (S.R.C.), California Pacific Medical Center Research Institute and the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Cosman","sequence":"additional","affiliation":[{"name":"Regional Bone Center (F.C.), Helen Hayes Hospital, West Haverstraw, New York 10993"},{"name":"Department of Medicine (F.C.), Columbia University College of Physicians and Surgeons, New York, New York 10032"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"3","key":"key\n\t\t\t\t2019041113504309100_B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"key\n\t\t\t\t2019041113504309100_B2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"22","key":"key\n\t\t\t\t2019041113504309100_B3","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update. A guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"issue":"25","key":"key\n\t\t\t\t2019041113504309100_B4","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report","volume":"106","author":"Third Report of the National Cholesterol Education Program (NCEP)","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"key\n\t\t\t\t2019041113504309100_B5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113504309100_B6","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20132012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"issue":"9290","key":"key\n\t\t\t\t2019041113504309100_B7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","article-title":"Cardiovascular protection and blood pressure reduction: a meta-analysis","volume":"358","author":"Staessen","year":"2001","journal-title":"Lancet"},{"issue":"19","key":"key\n\t\t\t\t2019041113504309100_B8","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.294.19.2492","article-title":"The IDEAL cholesterol: lower is better","volume":"294","author":"Cannon","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113504309100_B9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"issue":"9131","key":"key\n\t\t\t\t2019041113504309100_B10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2010.128462","article-title":"\u2018Treat to target\u2019: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis","volume":"69","author":"Atar","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"key\n\t\t\t\t2019041113504309100_B12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/CIRCOUTCOMES.111.964676","article-title":"Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health","volume":"5","author":"Hayward","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"key\n\t\t\t\t2019041113504309100_B13","first-page":"1643","article-title":"Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis","volume":"24","author":"Lewiecki","year":"2009","journal-title":"Endocr Pract"},{"issue":"9","key":"key\n\t\t\t\t2019041113504309100_B14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.7326\/0003-4819-154-9-201105030-00008","article-title":"Individualized guidelines: the potential for increasing quality and reducing costs","volume":"154","author":"Eddy","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113504309100_B15","unstructured":"National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http:\/\/www.nof.org\/files\/nof\/public\/content\/file\/344\/upload\/159.pdf. Accessed January 3, 2013."},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/JBMR.041214","article-title":"Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study","volume":"20","author":"Delmas","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0002-9343(00)00457-5","article-title":"Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture","volume":"109","author":"Kamel","year":"2000","journal-title":"Am J Med"},{"issue":"9","key":"key\n\t\t\t\t2019041113504309100_B18","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00198-008-0829-2","article-title":"Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures","volume":"20","author":"Sheehy","year":"2009","journal-title":"Osteoporos Int"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jocd.2006.07.002","article-title":"DXA quality matters","volume":"9","author":"Lewiecki","year":"2006","journal-title":"J Clin Densitom"},{"issue":"7","key":"key\n\t\t\t\t2019041113504309100_B20","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jocd.2011.07.006","article-title":"Going on a drug holiday?","volume":"14","author":"Bonnick","year":"2011","journal-title":"J Clin Densitom"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B22","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key\n\t\t\t\t2019041113504309100_B23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3949\/ccjm.78a.11022","article-title":"What is the optimal duration of bisphosphonate therapy?","volume":"78","author":"Ott","year":"2011","journal-title":"Cleve Clin J Med"},{"issue":"22","key":"key\n\t\t\t\t2019041113504309100_B24","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113504309100_B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr Pract"},{"issue":"1","key":"key\n\t\t\t\t2019041113504309100_B26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","author":"North American Menopause Society","year":"2010","journal-title":"Menopause"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11154-010-9126-4","article-title":"Monitoring pharmacological therapy for osteoporosis","volume":"11","author":"Lewiecki","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"key\n\t\t\t\t2019041113504309100_B28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference","volume":"11","author":"Baim","year":"2008","journal-title":"J Clin Densitom"},{"issue":"10","key":"key\n\t\t\t\t2019041113504309100_B29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-008-0661-8","article-title":"Assessing response to osteoporosis therapy","volume":"19","author":"Lewiecki","year":"2008","journal-title":"Osteoporos Int"},{"issue":"12","key":"key\n\t\t\t\t2019041113504309100_B30","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"issue":"5","key":"key\n\t\t\t\t2019041113504309100_B31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2005.11.001","article-title":"Fragility fractures and the osteoporosis care gap: an international phenomenon","volume":"35","author":"Giangregorio","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041113504309100_B32","volume-title":"Assessment of osteoporosis at the primary health-care level","author":"Kanis","year":"2007"},{"key":"key\n\t\t\t\t2019041113504309100_B33","unstructured":"World Health Organization. FRAX WHO fracture risk assessment tool. http:\/\/www.shef.ac.uk\/FRAX\/. 2012. Accessed January 3, 2013."},{"key":"key\n\t\t\t\t2019041113504309100_B34","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","author":"World Health Organization","year":"1994"},{"issue":"5","key":"key\n\t\t\t\t2019041113504309100_B35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"24","key":"key\n\t\t\t\t2019041113504309100_B36","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113504309100_B37","first-page":"S79","article-title":"Who is at highest risk for new vertebral fractures after 3 years of annual zoledronic acid and who should remain on treatment?","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key\n\t\t\t\t2019041113504309100_B38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113504309100_B39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"issue":"8","key":"key\n\t\t\t\t2019041113504309100_B40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"12","key":"key\n\t\t\t\t2019041113504309100_B41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","article-title":"Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD","volume":"20","author":"Watts","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"key\n\t\t\t\t2019041113504309100_B42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1359\/jbmr.081256","article-title":"Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment","volume":"24","author":"Watts","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"8","key":"key\n\t\t\t\t2019041113504309100_B43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Jacques","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key\n\t\t\t\t2019041113504309100_B44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key\n\t\t\t\t2019041113504309100_B45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","article-title":"Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club","volume":"63","author":"Bergmann","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"5","key":"key\n\t\t\t\t2019041113504309100_B46","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","article-title":"Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key\n\t\t\t\t2019041113504309100_B47","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key\n\t\t\t\t2019041113504309100_B48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2014a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key\n\t\t\t\t2019041113504309100_B49","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113504309100_B50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"issue":"4","key":"key\n\t\t\t\t2019041113504309100_B51","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","article-title":"A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX","volume":"47","author":"Kanis","year":"2010","journal-title":"Bone"},{"issue":"8","key":"key\n\t\t\t\t2019041113504309100_B52","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","article-title":"A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"issue":"8","key":"key\n\t\t\t\t2019041113504309100_B53","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jbmr.1625","article-title":"Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial","volume":"27","author":"Donaldson","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113504309100_B54","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.s4-b.1","article-title":"Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report","volume":"18","author":"Levis","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t2019041113504309100_B55","unstructured":"Garvan Institute. Fracture risk calculator. http:\/\/www.garvan.org.au\/bone-fracture-risk\/. 2010. Accessed January 3, 2013."},{"issue":"6","key":"key\n\t\t\t\t2019041113504309100_B56","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00198-010-1445-5","article-title":"Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts","volume":"22","author":"Leslie","year":"2011","journal-title":"Osteoporos Int"},{"issue":"10","key":"key\n\t\t\t\t2019041113504309100_B57","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/jbmr.230","article-title":"The evolution of fracture risk estimation","volume":"25","author":"Binkley","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"17","key":"key\n\t\t\t\t2019041113504309100_B58","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"issue":"10","key":"key\n\t\t\t\t2019041113504309100_B59","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX\u2014assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"9","key":"key\n\t\t\t\t2019041113504309100_B60","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","article-title":"Interpretation and use of FRAX in clinical practice","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"issue":"6","key":"key\n\t\t\t\t2019041113504309100_B61","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.1582","article-title":"Does osteoporosis therapy invalidate FRAX for fracture prediction?","volume":"27","author":"Leslie","year":"2012","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/3\/946\/10420462\/jcem0946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T12:18:08Z","timestamp":1644149888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/3\/946\/2536562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-3680","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,1]]}}}